These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients. Oh JH; Lee JM; Lee HJ; Hwang J; Lee CH; Cho YK; Park HS; Yoon HJ; Chung JW; Kim H; Nam CW; Han S; Hur SH; Youn JC; Kim IC ESC Heart Fail; 2022 Aug; 9(4):2435-2444. PubMed ID: 35484930 [TBL] [Abstract][Full Text] [Related]
6. Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure. Sabbah HN; Gupta RC; Kohli S; Wang M; Hachem S; Zhang K Circ Heart Fail; 2016 Feb; 9(2):e002206. PubMed ID: 26839394 [TBL] [Abstract][Full Text] [Related]
7. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF. Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633 [TBL] [Abstract][Full Text] [Related]
8. Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF. Visco V; Radano I; Campanile A; Ravera A; Silverio A; Masarone D; Pacileo G; Correale M; Mazzeo P; Dattilo G; Giallauria F; Cuomo A; Mercurio V; Tocchetti CG; Di Pietro P; Carrizzo A; Citro R; Galasso G; Vecchione C; Ciccarelli M ESC Heart Fail; 2022 Oct; 9(5):2909-2917. PubMed ID: 35702942 [TBL] [Abstract][Full Text] [Related]
10. Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction. Docherty KF; Campbell RT; Brooksbank KJM; Dreisbach JG; Forsyth P; Godeseth RL; Hopkins T; Jackson AM; Lee MMY; McConnachie A; Roditi G; Squire IB; Stanley B; Welsh P; Jhund PS; Petrie MC; McMurray JJV Circulation; 2021 Jul; 144(3):199-209. PubMed ID: 33983794 [TBL] [Abstract][Full Text] [Related]
11. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. Damman K; Gori M; Claggett B; Jhund PS; Senni M; Lefkowitz MP; Prescott MF; Shi VC; Rouleau JL; Swedberg K; Zile MR; Packer M; Desai AS; Solomon SD; McMurray JJV JACC Heart Fail; 2018 Jun; 6(6):489-498. PubMed ID: 29655829 [TBL] [Abstract][Full Text] [Related]
12. Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF. Myhre PL; Prescott MF; Murphy SP; Fang JC; Mitchell GF; Ward JH; Claggett B; Desai AS; Solomon SD; Januzzi JL JACC Heart Fail; 2022 Feb; 10(2):119-128. PubMed ID: 35115085 [TBL] [Abstract][Full Text] [Related]
13. Sacubitril/Valsartan Decreases Cardiac Fibrosis in Left Ventricle Pressure Overload by Restoring PKG Signaling in Cardiac Fibroblasts. Burke RM; Lighthouse JK; Mickelsen DM; Small EM Circ Heart Fail; 2019 Apr; 12(4):e005565. PubMed ID: 30998392 [TBL] [Abstract][Full Text] [Related]
14. Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin-Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure. Albert NM; Swindle JP; Buysman EK; Chang C J Am Heart Assoc; 2019 May; 8(9):e011089. PubMed ID: 31023122 [TBL] [Abstract][Full Text] [Related]
15. Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in Myakala K; Jones BA; Wang XX; Levi M Am J Physiol Renal Physiol; 2021 Jun; 320(6):F1133-F1151. PubMed ID: 33870733 [TBL] [Abstract][Full Text] [Related]
16. Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. Mohebi R; Liu Y; Felker GM; Prescott MF; Ward JH; Piña IL; Butler J; Solomon SD; Januzzi JL J Card Fail; 2022 Dec; 28(12):1673-1682. PubMed ID: 36122820 [TBL] [Abstract][Full Text] [Related]
17. The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat. Habibi J; Aroor AR; Das NA; Manrique-Acevedo CM; Johnson MS; Hayden MR; Nistala R; Wiedmeyer C; Chandrasekar B; DeMarco VG Cardiovasc Diabetol; 2019 Mar; 18(1):40. PubMed ID: 30909895 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and Pharmacodynamics of Sacubitril/Valsartan in Maintenance Hemodialysis Patients with Heart Failure. Feng Z; Wang X; Zhang L; Apaer R; Xu L; Ma J; Li X; Che H; Tang B; Xiong Y; Xia Y; Xiao J; Su X; Wang Y; Dou X; Chen J; Mei L; Xue Z; Kong Y; Li S; Zhang H; Lin T; Wen F; Fu X; Tao Y; Fu L; Li Z; Huang R; Ye Z; He C; Shi W; Liang X; Ke G; Liu S Blood Purif; 2022; 51(3):270-279. PubMed ID: 34753147 [TBL] [Abstract][Full Text] [Related]
19. Differential Effects of Sacubitril/Valsartan on Diastolic Function in Mice With Obesity-Related Metabolic Heart Disease. Croteau D; Qin F; Chambers JM; Kallick E; Luptak I; Panagia M; Pimentel DR; Siwik DA; Colucci WS JACC Basic Transl Sci; 2020 Sep; 5(9):916-927. PubMed ID: 33015414 [TBL] [Abstract][Full Text] [Related]